Foghorn Therapeutics Inc. (FHTX) - Q1 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2026. Foghorn Therapeutics Inc. is a clinical-stage biopharmaceutical company developing medicines targeting the chromatin regulatory system using its proprietary Gene Traffic Control platform. The company has no approved products and relies on collaboration revenue and equity financing. As of April 30, 2026, there were 58,713,922 shares of common stock outstanding.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Collaboration Revenue | $3.3 million | $6.0 million |
| Net Loss | $(19.9) million | $(18.8) million |
| Net Loss Per Share (Basic/Diluted) | $(0.29) | $(0.30) |
| Operating Expenses | $24.8 million | $28.9 million |
| Cash, Cash Equivalents & Marketable Securities | $183.6 million | $138.9 million (implied) |
| Accumulated Deficit | $(652.3) million | $(577.0) million |
| Deferred Revenue | $245.9 million | $249.2 million |
Material Changes vs. Prior Period
- Revenue Decline: Collaboration revenue decreased by $2.7 million (45%) to $3.3 million, attributed to the timing of work performed under the Eli Lilly collaboration agreement.
- Expense Reduction: Total operating expenses decreased by $4.0 million to $24.8 million.
- R&D Expenses: Decreased $3.4 million, driven by lower costs for Lilly partnered programs ($2.3M), discontinued FHD-286 program ($0.8M), and reduced facility costs ($2.0M). This was partially offset by a $2.6M increase in early development and platform research costs.
- G&A Expenses: Decreased $0.7 million, primarily due to lower facility and IT costs.
- Financing Activity: In January 2026, the company completed an offering raising approximately $50.0 million in gross proceeds through the sale of common stock, pre-funded warrants, and series warrants. Net cash provided by financing activities was $49.8 million.
- Other Income: Other income, net, decreased by $2.4 million to $1.7 million, primarily due to the conclusion of sublease income in 2025 and lower interest income.
Guidance, Outlook, and Risks
- Liquidity: Management expects cash, cash equivalents, and marketable securities ($183.6 million as of March 31, 2026) to be sufficient to fund operations for at least 12 months from the issuance date.
- Pipeline Updates:
- FHD-909: Phase 1 dose escalation study with Eli Lilly is ongoing (first patient dosed Oct 2024).
- FHD-286: Independent development was discontinued in December 2024, resulting in cost savings.
- Risks: The company faces significant risks regarding the need for additional financing, the success of clinical trials, and reliance on the Eli Lilly collaboration. The company is currently under an IRS audit for the tax year ended December 31, 2023.
- Forward-Looking Statements: The filing contains predictions regarding clinical trial timing, regulatory approvals, and capital needs, which are subject to significant uncertainties.
Investor Verification Checklist
- Verify the burn rate and runway based on the $183.6 million cash position against the $25.3 million quarterly operating cash burn.
- Confirm the status and enrollment progress of the FHD-909 Phase 1 trial with Eli Lilly.
- Review the terms of the January 2026 offering, specifically the exercise prices and expiration dates of the Series 1 and Series 2 warrants.
- Monitor the outcome of the ongoing IRS audit for the 2023 tax year.
- Assess the impact of the discontinued FHD-286 program on the overall pipeline strategy and future R&D allocation.